Vernalis plc



Vernalis plc, the parent company of Vernalis Therapeutics, Inc. is one of the UK’s leading pharmaceutical companies, Vernalis takes promising product candidates along a commercially-focused path to market. We derive pipeline candidates both from successful collaborations with a number of global pharmaceutical businesses, our own research activities and from in-licensing. 

 The strategy is to:

  • Build a profitable and cash generative business
  • Develop and commercialise low development-risk late-stage differentiated pharmaceutical products for unmet medical needs in the US
  • Partner all of our NCE drug candidates
  • Leverage our structure- and fragment-based drug discovery expertise through collaborations with other companies

For more information please visit us at


Latest News

Results Announcement for the year ended 30 June 2017

Vernalis plc (LSE: VER) today announces its audited financial results for the year ended 30 June 2017, following the year-end trading update published on 18 July 2017.

Read more ...

Fact Sheet

For more information on Vernalis, click below to download a copy of our fact sheet







Contact Vernalis Therapeutics

T: 1-484-913-0700
F: 1-610-651 5976

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and or FDA at 1-800-FDA-1088 or